Sarabi Matthieu, Perraud Aurélie, Mazouffre Clément, Nouaille Michelle, Jauberteau Marie-Odile, Mathonnet Muriel
Department of Hepato-Gastro-Enterology, University of Limoges Teaching Hospital, F-87042 Limoges Cedex, France; Department of Medical Oncology, Léon Bérard Center, F-69008 Lyon, France.
Department of Digestive, General and Endocrinal Surgery, University of Limoges Teaching Hospital, F-87042 Limoges Cedex, France; Laboratory EA 3842, Cellular Homeostasis and Pathologies, Medicine and Pharmacy Faculties, University of Limoges, F-87025 Limoges Cedex, France; CNRS 3503 Department, Federative Research Institute, Genomic, Environment, Immunity, Health and Therapeutics, University of Limoges, F-87025 Limoges Cedex, France.
Biomed Rep. 2017 Jan;6(1):89-94. doi: 10.3892/br.2016.801. Epub 2016 Nov 7.
Previous studies have reported the association between brain-derived neurotrophic factor (BDNF) and tumor development in numerous cancers. However, the accurate implication of the two specific ligands of tropomyosin kinase B receptor, BDNF and neurotrophic factor 4 (NT4/5), has not been studied in colorectal cancer (CRC) patients. The present study investigated the significance of serum BDNF and the NT4/5 in association with the intake of psychoactive drugs in CRC patients. Soluble BDNF and NT4 in the serum were assessed by ELISA. Although no correlation of BDNF and NT4 with the CRC stage was identified, a positive correlation was found between NT4 and the intake of psychoactive drugs (P=0.0457). For BDNF, a correlation was found in particular with the intake of benzodiazepine (P=0.0221). As BDNF and NT4/5 are implicated in the response of psychoactive treatments applied to manage depression, which frequently occurs in cancer patients, they cannot be used as prognostic or diagnostic markers for CRC in these patients. However, high expression of BDNF and NT4 was significantly associated with better survival. Therefore, these NTs may be used as markers for monitoring depression or predicting survival in CRC patients.
先前的研究报道了脑源性神经营养因子（BDNF）与多种癌症肿瘤发生之间的关联。然而，尚未在结直肠癌（CRC）患者中研究原肌球蛋白激酶B受体的两种特异性配体BDNF和神经营养因子4（NT4/5）的确切影响。本研究调查了血清BDNF和NT4/5与CRC患者精神活性药物摄入之间关联的意义。通过酶联免疫吸附测定法（ELISA）评估血清中的可溶性BDNF和NT4。虽然未发现BDNF和NT4与CRC分期之间存在相关性，但发现NT4与精神活性药物的摄入呈正相关（P=0.0457）。对于BDNF，特别发现其与苯二氮䓬类药物的摄入存在相关性（P=0.0221）。由于BDNF和NT4/5与用于治疗癌症患者中经常出现的抑郁症的精神活性治疗反应有关，因此它们不能用作这些患者CRC的预后或诊断标志物。然而，BDNF和NT4的高表达与更好的生存率显著相关。因此，这些神经营养因子可作为监测CRC患者抑郁症或预测其生存率的标志物。
